A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)
Launched by TAIHO PHARMACEUTICAL CO., LTD. · Sep 8, 2005
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 20 to 75
- • Performance status 0 , 1, or 2 (ECOG)
- • Hematopoietic WBC ≥ 4,000/mm\^3 Platelet ≥ 100,000/mm\^3
- • Hepatic AST and ALT ≤ 2 times upper limit of normal(ULN) Total bilirubin ≤ 1.5 times ULN
- • Renal BUN ≤1.5 times ULN Creatinine ≤ 1.5 times ULN
- Exclusion Criteria:
- • Prior anticancer treatment
About Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. is a leading global biopharmaceutical company based in Japan, dedicated to the research, development, manufacturing, and marketing of innovative therapeutic solutions. With a strong focus on oncology, gastroenterology, and other therapeutic areas, Taiho leverages cutting-edge science and technology to address significant unmet medical needs. The company is committed to advancing healthcare through rigorous clinical trials and collaborations, ensuring the highest standards of quality and safety in its product offerings. Taiho Pharmaceutical's dedication to improving patient outcomes reflects its core mission of contributing to the well-being of society through the advancement of pharmaceutical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
3 10 6, Ariake, Koto Ku, Tokyo, Japan
Patients applied
Trial Officials
Toshifusa Nakajima, MD
Principal Investigator
Cancer Institute Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials